Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsOpinionLupin and peers run into US FDA headwinds again

    Lupin and peers run into US FDA headwinds again

    Lupin’s shares fell after an FDA inspection led to its US unit being issued an adverse warning. Other pharma companies too have tripped on inspections, raising fears that compliance issues are very much alive for the industry

    Ravi Ananthanarayanan
    March 18, 2019 / 18:25 IST
    • PRO Panorama

      Moneycontrol Pro Panorama | Good tidings for Indian IT from Accenture's results

      Dec 19, 2025 / 03:21 PM IST

      For Moneycontrol's Pro Panorama December 19 edition: Growth strong but jobs lag behind, a look at India’s coal growth story, wha...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts